Digest Network Come funziona
Network
/
Società
Io
Non verificato

Ionis Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

55 comunicati stampa

Guarda tutti i comunicati
09/03/2026
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Ionis announces changes to Board of Directors
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
27/02/2026
Eventi
Salute
Biotecnologia
Scienza
Farmaceutica
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
26/02/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
19/02/2026
Eventi
Web e Social Network
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Ionis to present at upcoming investor conferences
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
17/02/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Biotecnologia
Farmaceutica
Cardiologia
Ionis updates time for fourth quarter and full year 2025 financial results webcast
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/02/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Biotecnologia
Farmaceutica
Cardiologia
Ionis to hold fourth quarter and full year 2025 financial results webcast
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
21/01/2026
HIV, AIDS e malattie autoimmuni
Biotecnologia
Farmaceutica
Salute
Mercato del lavoro
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Industria
Cardiologia
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/01/2026
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0